These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 29151192)

  • 1. Impact of oral ketamine augmentation on hospital admissions in treatment-resistant depression and PTSD: a retrospective study.
    Hartberg J; Garrett-Walcott S; De Gioannis A
    Psychopharmacology (Berl); 2018 Feb; 235(2):393-398. PubMed ID: 29151192
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral ketamine augmentation for chronic suicidality in treatment-resistant depression.
    De Gioannis A; De Leo D
    Aust N Z J Psychiatry; 2014 Jul; 48(7):686. PubMed ID: 24452289
    [No Abstract]   [Full Text] [Related]  

  • 3. Efficacy, Safety, and Durability of Repeated Ketamine Infusions for Comorbid Posttraumatic Stress Disorder and Treatment-Resistant Depression.
    Albott CS; Lim KO; Forbes MK; Erbes C; Tye SJ; Grabowski JG; Thuras P; Batres-Y-Carr TM; Wels J; Shiroma PR
    J Clin Psychiatry; 2018; 79(3):. PubMed ID: 29727073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploring a post-traumatic stress disorder paradigm in Flinders sensitive line rats to model treatment-resistant depression II: response to antidepressant augmentation strategies.
    Brand SJ; Harvey BH
    Acta Neuropsychiatr; 2017 Aug; 29(4):207-221. PubMed ID: 27692010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ketamine augmentation for outpatients with treatment-resistant depression: Preliminary evidence for two-step intravenous dose escalation.
    Cusin C; Ionescu DF; Pavone KJ; Akeju O; Cassano P; Taylor N; Eikermann M; Durham K; Swee MB; Chang T; Dording C; Soskin D; Kelley J; Mischoulon D; Brown EN; Fava M
    Aust N Z J Psychiatry; 2017 Jan; 51(1):55-64. PubMed ID: 26893373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The intraoperative administration of ketamine to burned U.S. service members does not increase the incidence of post-traumatic stress disorder.
    McGhee LL; Maani CV; Garza TH; Slater TM; Petz LN; Fowler M
    Mil Med; 2014 Aug; 179(8 Suppl):41-6. PubMed ID: 25102548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Can we confidently use ketamine as a clinical treatment for depression?
    Loo C
    Lancet Psychiatry; 2018 Jan; 5(1):11-12. PubMed ID: 29277196
    [No Abstract]   [Full Text] [Related]  

  • 8. Effects of ketamine on major depressive disorder in a patient with posttraumatic stress disorder.
    Womble AL
    AANA J; 2013 Apr; 81(2):118-9. PubMed ID: 23971230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Side-effects associated with ketamine use in depression: a systematic review.
    Short B; Fong J; Galvez V; Shelker W; Loo CK
    Lancet Psychiatry; 2018 Jan; 5(1):65-78. PubMed ID: 28757132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ketamine and Treatment-Resistant Depression.
    Lent JK; Arredondo A; Pugh MA; Austin PN
    AANA J; 2019 Oct; 87(5):411-419. PubMed ID: 31612847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Promises and concerns regarding the use of ketamine and esketamine in the treatment of depression.
    Pérez-Esparza R; Kobayashi-Romero LF; García-Mendoza AM; Lamas-Aguilar RM; Fonseca-Perezamador A
    Acta Psychiatr Scand; 2019 Aug; 140(2):182-183. PubMed ID: 31251388
    [No Abstract]   [Full Text] [Related]  

  • 12. Increased Reactivity of the Mesolimbic Reward System after Ketamine Injection in Patients with Treatment-resistant Major Depressive Disorder.
    Sterpenich V; Vidal S; Hofmeister J; Michalopoulos G; Bancila V; Warrot D; Dayer A; Desseilles M; Aubry JM; Kosel M; Schwartz S; Vutskits L
    Anesthesiology; 2019 Jun; 130(6):923-935. PubMed ID: 31021848
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
    Feder A; Parides MK; Murrough JW; Perez AM; Morgan JE; Saxena S; Kirkwood K; Aan Het Rot M; Lapidus KA; Wan LB; Iosifescu D; Charney DS
    JAMA Psychiatry; 2014 Jun; 71(6):681-8. PubMed ID: 24740528
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pediatric procedural sedation with ketamine: time to discharge after intramuscular versus intravenous administration.
    Ramaswamy P; Babl FE; Deasy C; Sharwood LN
    Acad Emerg Med; 2009 Feb; 16(2):101-7. PubMed ID: 19076105
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Placebo-controlled pilot trial testing dose titration and intravenous, intramuscular and subcutaneous routes for ketamine in depression.
    Loo CK; Gálvez V; O'Keefe E; Mitchell PB; Hadzi-Pavlovic D; Leyden J; Harper S; Somogyi AA; Lai R; Weickert CS; Glue P
    Acta Psychiatr Scand; 2016 Jul; 134(1):48-56. PubMed ID: 27028832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Switching to Intranasal Esketamine Maintains the Antidepressant Response to Intravenous Racemic Ketamine Administration: A Case Series of 10 Patients.
    Banov MD; Landrum RE; Moore MB; Szabo ST
    J Clin Psychopharmacol; 2021 Sep-Oct 01; 41(5):594-599. PubMed ID: 34411009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Augmentation of response and remission to serial intravenous subanesthetic ketamine in treatment resistant depression.
    Shiroma PR; Johns B; Kuskowski M; Wels J; Thuras P; Albott CS; Lim KO
    J Affect Disord; 2014 Feb; 155():123-9. PubMed ID: 24268616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dissociative symptoms with intravenous ketamine in treatment-resistant depression exploratory observational study.
    Włodarczyk A; Cubała WJ; Gałuszko-Węgielnik M; Szarmach J
    Medicine (Baltimore); 2021 Jul; 100(29):e26769. PubMed ID: 34398056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravenous ketamine infusion for a patient with treatment-resistant major depression: a 10-month follow-up.
    Kwon JH; Sim WS; Hong JP; Song IS; Lee JY
    J Clin Pharm Ther; 2018 Aug; 43(4):581-583. PubMed ID: 29372569
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single i.v. ketamine augmentation of newly initiated escitalopram for major depression: results from a randomized, placebo-controlled 4-week study.
    Hu YD; Xiang YT; Fang JX; Zu S; Sha S; Shi H; Ungvari GS; Correll CU; Chiu HF; Xue Y; Tian TF; Wu AS; Ma X; Wang G
    Psychol Med; 2016 Feb; 46(3):623-35. PubMed ID: 26478208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.